Results from two randomised trials comparing primary chemotherapy including taxanes and anthracyclines plus/minus trastuzumab indicated that the clinical course of HER2-positive breast cancer can be modified by the preoperative use of targeted therapies (Buzdar et al, 2007; Gianni et al, 2007). This evidence concerns the gene ERBB2 and breast carcinoma.